Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Japan Deeping Debate on LLP Copay Review; Focus Is on Exclusion Criteria, Payment Levels, G1/G2 Rule Change
November 27, 2023
- Japan Approves Label Expansions for Opdivo, Adcetris, and More
November 27, 2023
- Japan Grants Orphan Tags to MSD’s MK-3475A, 3 More Drugs
November 27, 2023
- COVID Vaccines to Join NIP for Ages 65-Plus from April, with Copay Required
November 24, 2023
- No Objections to Better Premiums, Easing of Re-Pricing as Incentives for Pediatric Drug Development: Chuikyo
November 24, 2023
- Chuikyo Reps Split on Nixing PMP Company Criteria; Many Back Review of Reduction Caps under Re-Pricing
November 24, 2023
- MHLW Proposes Posting Reported Drug Supply Concerns on Its Website
November 22, 2023
- Label Revisions Ordered for 5 Anticoagulants Agents
November 22, 2023
- LDP Health Division Head Calls for “Innovation Box” Tax Break: Hearing
November 22, 2023
- Chuikyo Offers No Objection to MHLW Proposal on SaMD Reimbursement Criteria
November 21, 2023
- MHLW Notification Outlines 2-Stage Approval Scheme for SaMD
November 21, 2023
- Provide “One-Stop Services” to Facilitate Multiregional Clinical Trials: Expert
November 21, 2023
- 1st G-Lasta Biosimilar Gets Japan Listing, Stelara Follow-On Not on Roster
November 21, 2023
- LDP Study Group Submits Proposal for FY2024 Reform, Urges Boosted Drug Price Premiums at Launch
November 21, 2023
- MOF Panel Renews Call for Full Execution of Annual Price Cuts, Urges LLP Copay Review: Budget Proposal
November 21, 2023
- Pilot Sales of Emergency Contraceptives without Prescription to Start on Nov. 28
November 20, 2023
- Japan to Adopt Generic Company Indices for Drug Pricing on Pilot Basis from FY2024
November 20, 2023
- Pharma Fiercely Opposes Proposed CEA Cut into Drug Base Price: Chuikyo Hearing
November 20, 2023
- Japan Agrees to Buy 1.4 Million Doses of Daiichi Sankyo’s COVID Vaccine
November 17, 2023
- LDP Raises Stable Drug Supply as Major Topic of FY2024 Budget Formulation
November 17, 2023
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…